Factbites
 Where results make sense
About us   |   Why use us?   |   Reviews   |   PR   |   Contact us  

Topic: ZymoGenetics


Related Topics

  
  ZymoGenetics - Wikipedia, the free encyclopedia
ZymoGenetics is a biotechnology/pharmaceutical company based in Seattle, Washington involved in the development of therapeutic proteins.
The company was founded in 1981 by Professors Earl W. Davie and Benjamin D. Hall of the University of Washington and 1993 Nobel Laureate in Chemistry Michael Smith of the University of British Columbia.
ZymoGenetics' headquarters are in the landmark Lake Union Steam Plant building, built from 1914 to 1921 by Seattle City Light, the municipal electric utility.
en.wikipedia.org /wiki/ZymoGenetics   (188 words)

  
 ZymoGenetics News
ZymoGenetics, Inc. and Serono today announced favorable results from a Phase 1b clinical trial with TACI-Ig in 73 patients with rheumatoid arthritis, recently presented at the 7th Annual European Congress of...
ZymoGenetics said today it has finished enrolling patients in a final-stage clinical trial of its Thrombin treatment for surgical bleeding.
ZymoGenetics, Inc. today announced it has completed patient enrollment for a Phase 3 pivotal clinical trial of recombinant human thrombin as an aid to controlling blood loss during surgery.
www.topix.net /com/zgen   (598 words)

  
 ZymoGenetics   (Site not responding. Last check: 2007-10-12)
ZymoGenetics is developing recombinant human Factor XIII (rFactor XIII) for the prophylaxis and treatment of bleeding complications and alterations in tissue repair associated with Factor XIII deficiencies.
ZymoGenetics intends to test rFactor XIII initially in patients with congenital Factor XIII deficiency (of which there is one case for every 2-5 million people) and then move into clinical indications with significantly larger market opportunities.
ZymoGenetics is developing rFactor XIII for treatment of bleeding complications and alterations in tissue repair associated with Factor XIII deficiencies.
www.zgi.com /products/factor-xiii.html   (1295 words)

  
 ZymoGenetics
ZymoGenetics Begins Phase 1 Trial With IL-21 and Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
ZymoGenetics Reports Encouraging IL-21 Phase 1b Results in Metastatic Melanoma and Renal Cell Cancer Presented at ASCO Meeting
ZymoGenetics to Begin Clinical Study with Interleukin 21; FDA gives go ahead to proceed with Phase 1 cancer study
www.zgi.com /clinical/il-21.html   (495 words)

  
 ZymoGenetics researchers identify novel Interleukin that plays key role in immune system regulation
"ZymoGenetics was early to recognize the value of mining the human genome for the discovery of novel therapeutic proteins," said Bruce L. Carter, Ph.D., President and Chief Executive Officer of ZymoGenetics.
ZymoGenetics researchers describe for the first time the identification of IL-21 ligand, and the interaction of IL-21 and its receptor, IL-21R, two proteins that are members of the family of molecules known as Class I cytokines and Class I cytokine receptors.
ZymoGenetics is a leading biopharmaceutical company focused on the discovery and development of protein therapeutics that prevent or treat significant human diseases.
www.eurekalert.org /pub_releases/2000-11/FKH-Zrin-0111100.php   (751 words)

  
 BIO.COM: Biotechnology Pharmaceutical Market, Stocks, Finance, Merger, Acquisition - Biotech, Pharma, Biomedical   (Site not responding. Last check: 2007-10-12)
ZymoGenetics is currently finalizing plans for the rhThrombin Phase 3 pivotal trial.
ZymoGenetics is developing rhThrombin for the control of bleeding associated with surgical procedures.
ZymoGenetics is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic proteins for the prevention or treatment of human diseases.
www.bio.com /industryanalysis/industryanalysis_news.jhtml?cid=12800047   (447 words)

  
 Medical World Communications
ZymoGenetics is exploring additional indications for IL-21 and anticipates filing an Investigational New Drug application in 2005 to test the use of IL-21 in combination with the monoclonal antibody Rituxan(R).
ZymoGenetics is considering pursuing a Special Protocol Assessment (SPA) for the rhThrombin pivotal Phase 3 trial.
ZymoGenetics is developing TACI-Ig in collaboration with Serono S.A. and is conducting Phase 1b studies in patients with SLE, rheumatoid arthritis, and in patients with B-cell malignancies.
www.mwc.com /NewsfeedArticle.cfm?NewsID=7593   (1405 words)

  
 Stockwatch > News > News Item   (Site not responding. Last check: 2007-10-12)
ZymoGenetics completed Phase 1 studies to evaluate the safety and pharmacokinetics of rFactor XIII in patients with congenital Factor XIII deficiency and to evaluate the safety and pharmacokinetics in healthy volunteers.
ZymoGenetics is developing TACI-Ig in collaboration with Serono S.A. and is conducting Phase 1b studies in patients with SLE and rheumatoid arthritis.
ZymoGenetics is conducting a Phase 2 clinical study of rhThrombin in patients undergoing lumbar spine surgery, liver resection, lower extremity peripheral artery bypass surgery and formation of vascular access grafts for dialysis.
new.stockwatch.com /swnet/newsit/newsit_newsit.aspx?bid=U-b006268-U:ZGEN-20041004&symbol=ZGEN&news_region=U   (1448 words)

  
 ZymoGenetics, Inc.   (Site not responding. Last check: 2007-10-12)
ZymoGenetics is an independent biopharmaceutical company focused on the discovery and development of protein therapeutics for the prevention or treatment of significant human diseases.
ZymoGenetics was early to see the value of mining the human genome for the discovery of novel genes.
ZymoGenetics has 290 employees and is headquartered in the historic Seattle City Light building in Seattle, Washington.
www.acor.org /drugs/pipeline/companies/ZymoGenetics,+Inc..tmp   (228 words)

  
 Biotechnology News and Information Portal, biotech jobs and career resources Resources.
ZymoGenetics identified the novel cytokine family containing Interleukins 28A and 29 from human genomic sequence.
ZymoGenetics researchers found that like type I IFNs, IL-28A and IL-29 have antiviral activity and are induced by viral infection.
A paper by ZymoGenetics scientists that was published in the July 2004 issue of the journal Nature Immunology characterizes IL-31, illustrates the hypothesized role of IL-31 in atopic dermatitis and respiratory disease, and suggests directions for future investigation of this cytokine and its role in human diseases.
www.bioexchange.com /news/news_page.cfm?id=20640   (1029 words)

  
 ZymoGenetics Researchers Identify Novel Protein with Potential Role in Psoriasis   (Site not responding. Last check: 2007-10-12)
Scientists at ZymoGenetics discovered the human gene coding for IL-20, which belongs to a class of cytokines responsible for regulating a wide variety of cellular processes in both healthy and diseased tissues.
ZymoGenetics scientists further characterized the interaction between the IL-20 protein and a cell-surface receptor composed of two subunits, named IL-20R alpha and IL-20R beta, that are present in human skin cells.
About ZymoGenetics ZymoGenetics is an independent biopharmaceutical company focused on the discovery and development of protein therapeutics that prevent or treat significant human diseases.
www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/01-12-2001/0001402622&EDATE=   (667 words)

  
 ZymoGenetics Inc. Investor Relations
ZymoGenetics expects to file an IND for the most advanced of these, recombinant human Factor XIII, by the end of this year.
Previously, ZymoGenetics had announced its intention to spend approximately $50 million to construct a facility for the manufacture of GMP product for use in preclinical toxicology studies and early stage human clinical trials.
ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with biopharmaceutical partners, and out- licensing of its extensive patent portfolio.
www.corporate-ir.net /ireye/ir_site.zhtml?ticker=zgen&script=410&layout=6&item_id=301992   (528 words)

  
 Healthcare Sales & Marketing Network News: ZymoGenetics Announces Start of TACI-Ig Clinical Study in Lupus Patients
ZymoGenetics scientists further showed that mice genetically engineered to over express the gene for BlyS develop symptoms of SLE, including the generation of autoantibodies.
In published studies, scientists at ZymoGenetics demonstrated that in TACI transgenic mice, which are mice that have been genetically engineered to over express a soluble form of the TACI receptor, there are very few mature B cells and reduced levels of circulating antibody.
ZymoGenetics has reported data showing the effectiveness of TACI-Ig to inhibit the progression of autoimmune disease in mouse models of lupus and rheumatoid arthritis.
salesandmarketingnetwork.com /news_release.php?ID=16776   (1284 words)

  
 The Seattle Times: Business & Technology: ZymoGenetics cashes in on patents   (Site not responding. Last check: 2007-10-12)
Maybe the collection of patents ZymoGenetics holds on the human genome is starting to become more valuable after all.
ZymoGenetics stock rose 31 cents after the news to close at $16.79.
ZymoGenetics Chief Executive Bruce Carter said the company chose to sell the intellectual property rather than develop it in-house.
seattletimes.nwsource.com /html/businesstechnology/2001934736_zymo21.html   (487 words)

  
 ZymoGenetics Receives U.S. Patent on ADAM33 Protein
ZymoGenetics uses a focused approach in its bioinformatics-driven gene discovery efforts to search for those gene sequences that code for proteins with the greatest potential for becoming therapeutic proteins.
As a result of this focused approach, ZymoGenetics is building a broad intellectual property portfolio for potential therapeutic proteins, which include patents covering the disintegrin metalloprotease family.
About ZymoGenetics ZymoGenetics is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic proteins for the prevention or treatment of human diseases.
www.prnewswire.com /cgi-bin/stories.pl?ACCT=105&STORY=/www/story/07-18-2002/0001766662   (527 words)

  
 ZymoGenetics Completes Enrollment For RhThrombin Phase 3 Trial
ZymoGenetics, Inc. (Nasdaq: ZGEN) today announced it has completed patient enrollment for a Phase 3 pivotal clinical trial of recombinant human thrombin (rhThrombin) as an aid to controlling blood loss during surgery.
Assuming the endpoints in the study are met, ZymoGenetics plans to submit a Biologics Licensing Application (BLA) for rhThrombin to the FDA in late 2006.
ZymoGenetics creates novel protein drugs with the potential to significantly help patients fight their diseases.
www.pharma-lexicon.com /medicalnews.php?newsid=45557   (552 words)

  
 ZymoGenetics posts a $37 million loss   (Site not responding. Last check: 2007-10-12)
ZymoGenetics Inc., the Seattle biotechnology company that last week sued Immunex Corp. over patent infringement, said yesterday that it lost almost $37 million last year.
ZymoGenetics was founded in 1981 and is one of the region's largest biotechnology companies.
During the fourth quarter, ZymoGenetics said it lost $11.3 million, or $1.37 a share, compared with losses of $18.2 million, or $1.79 a share, the previous year.
seattlepi.nwsource.com /business/61842_zymo12.shtml   (603 words)

  
 ZymoGenetics discovers potential new therapy for autoimmune diseases
The immunosuppressive agent under investigation at ZymoGenetics, termed soluble "TACI," is a modified form of a receptor that is found on the surface of B cells.
ZymoGenetics, founded in 1981, currently leverages its expertise in bioinformatics and biology to discover and develop novel therapeutic proteins.
ZymoGenetics is headquartered in Seattle, Washington, has 280 employees, and serves as the primary US discovery arm of Novo Nordisk A/S. Novo Nordisk A/S is the world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products.
www.eurekalert.org /pub_releases/2000-04/NC-Zdpn-2604100.php   (808 words)

  
 KCTS/Seattle: The Public Network | KCTS Productions | Serious Money | Archive | #1025: ZymoGenetics, Safeco something
Seattle, Washington-based ZymoGenetics (Nasdaq: ZGEN) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic proteins to prevent or treat human diseases.
In November 2000, ZymoGenetics was reestablished as an independent biotech and it has recently gone public; it also announced last week that it is suing Seattle biotech rival Immunex for patent infringement.
We talk with ZymoGenetics CEO Bruce Carter about their growth into the third largest biotechnology firm in Washington state, their product candidates and the future of the company.
www.kcts.org /productions/seriousmoney/archive/episode_156.htm   (218 words)

  
 Apax Partners - ZymoGenetics   (Site not responding. Last check: 2007-10-12)
ZymoGenetics was a wholly-owned research affiliate of Novo Nordisk from 1988 to 2000.
As the primary US discovery arm for Novo Nordisk for 12 years, ZymoGenetics developed a broad intellectual property portfolio which is now being leveraged for both internal and external drug development.
In February 2002, ZymoGenetics completed a successful IPO on Nasdaq, which raised $120 million, and a secondary offering in October 2003, which raised $75 million.
www.apax.com /en/casestudies/881.html   (361 words)

  
 BioSpace News for ZymoGenetics   (Site not responding. Last check: 2007-10-12)
ZymoGenetics has granted the underwriters of the offering an option to purchase up to an additional 1,500,000 shares of its common stock to cover over-allotments, if any.
ZymoGenetics contemplates an offering of 10 million shares with a potential overallotment option (green shoe) of additionally 1.5 million shares.
Dr. Jane Gross, a Principal Scientist at ZymoGenetics, Inc., will present recent research findings and preclinical studies demonstrating the potential utility of the company's TACI receptor as an inhibitor of B cell activation and auto-antibody production, key mediators involved in development of autoimmune disease.
www.acor.org /drugs/pipeline/companies/news/4152.news.orig   (848 words)

  
 ZymoGenetics Begins Phase 1 Trial With IL-21 And Rituxan(R) In Patients With Non-Hodgkin's Lymphoma
ZymoGenetics, Inc. (Nasdaq: ZGEN) today announced that a Phase 1 clinical trial is underway using Interleukin 21 (IL-21) in combination with the monoclonal antibody Rituxan(R).
In these studies, after 90 days of follow-up, a combination of IL-21 plus low-dose Rituxan enabled survival of 70% of mice injected with an aggressive non-Hodgkin's lymphoma cell line, compared with only 10% that were treated with the same dose of Rituxan alone, and none that were treated with IL-21 alone.
Based upon the ability of IL-21 to inhibit tumor growth in a number of animal models, ZymoGenetics is developing IL-21 for the treatment of cancer and has retained commercialization rights for IL-21 in North America.
www.medicalnewstoday.com /medicalnews.php?newsid=47105&nfid=rssfeeds   (573 words)

  
 ZymoGenetics
ZymoGenetics, Inc. hereby authorizes you to copy these documents published by ZymoGenetics, Inc. on the World Wide Web for non-commercial use only, provided all copies, whether electronic or mechanical, including paper copies, retain all copyright, trademark, and other proprietary notices contained herein.
ZymoGenetics assumes no obligation to update any information contained in such press release, whether to reflect events or circumstances subsequent to the date of such press release or otherwise.
ZymoGenetics Inc. shall be free to use such information, including any ideas, concepts, know-how or techniques contained therein, for any purpose whatsoever including but not limited to researching, developing, manufacturing, selling and marketing products based upon or incorporating such information.
sf1000.registeredsite.com /~user891905/terms.html   (503 words)

  
 ZymoGenetics signs big deal
For ZymoGenetics, the alliance with Europe's largest biotechnology company provides a significant cash infusion, a powerful manufacturing partner and a deep bench of research talent that can help bring new drugs to market.
If ZymoGenetics decides not to participate in the development, the company could still receive milestone payments of as much as $55 million for each drug candidate.
ZymoGenetics will retain co-commercialization and co-development rights for IL-31, a drug that could be used to treat asthma, psoriasis and inflammatory bowel disease.
seattlepi.nwsource.com /business/190047_zymo09.html   (1112 words)

  
 Nasdaq MarketSite Event - ZymoGenetics, Inc. - 02/01/2002   (Site not responding. Last check: 2007-10-12)
ZymoGenetics, Inc. [ZGEN] is an independent biopharmaceutical company focused on the discovery, development and commercialization of therapeutic proteins for the prevention or treatment of human diseases.
ZymoGenetics intends to develop and commercialize its product candidates through internal development and direct marketing, development and marketing partnerships, and out-licensing of intellectual property and selected product candidates.
Today, ZymoGenetics is the third largest biotechnology firm in Washington state with approximately 300 employees.
www.nasdaq.com /reference/market_ipo_020102.stm   (143 words)

  
 ZYMOGENETICS INC - ZGEN Annual Report (10-K) EXHIBIT 10.39
ZymoGenetics, however, shall be responsible for the cost of non-routine maintenance and servicing of the Dedicated Equipment (such as major repairs and material parts replacement), except to the extent caused by Abbott's negligence, willful misconduct, unauthorized use or use with other products in which case Abbott shall be responsible.
Abbott warrants to ZymoGenetics that it has, and shall maintain in compliance with applicable laws and regulations during the term of this Agreement, the facilities, equipment, personnel, licenses and patents and expertise necessary to fulfill its obligations hereunder.
ZymoGenetics is developing rhThrombin as an alternative to bovine plasma-derived thrombin for use as a topical hemostat to control bleeding in a variety of surgical and wound healing settings.
sec.edgar-online.com /2004/03/29/0001193125-04-052427/section27.asp   (10439 words)

  
 RedOrbit - Health - ZymoGenetics Begins Phase 3 Clinical Study With Recombinant Human Thrombin; Conference Call Today ...   (Site not responding. Last check: 2007-10-12)
ZymoGenetics, Inc. (Nasdaq:ZGEN) today announced the start of a pivotal Phase 3 clinical study of recombinant human Thrombin (rhThrombin) in patients undergoing surgery.
ZymoGenetics will conduct a conference call/webcast in conjunction with today's release at 11:00 a.m.
Members of the news media, investors and the general public are invited to access a live broadcast of the conference call via the ZymoGenetics website at http://www.zymogenetics.com/ir/events.php or through www.vcall.com.
www.redorbit.com /news/health/285883/zymogenetics_begins_phase_3_clinical_study_with_recombinant_human_thrombin/index.html?source=r_health   (790 words)

Try your search on: Qwika (all wikis)

Factbites
  About us   |   Why use us?   |   Reviews   |   Press   |   Contact us  
Copyright © 2005-2007 www.factbites.com Usage implies agreement with terms.